Intensity Therapeutics Restarts Phase 2 TNBC Trial
SHELTON, Conn., July 15, 2026 Intensity Therapeutics, Inc. has restarted patient treatment in its Phase 2 INVINCIBLE-4 clinical trial...
AI drug discovery artificial intelligence ASCO 2026 Autoimmune Disease Bio-Pharma biologics biopharma Biopharmaceuticals Biotechnology Bispecific Antibody Cancer Immunotherapy Cancer Research cancer therapy Cell Therapy Clinical Development Clinical Research clinical trial clinical trials Digital Health drug development FDA fda approval FDA clearance Gene Therapy Healthcare Innovation healthcare technology Immuno-Oncology immunology Immunotherapy Medical Device Medical Devices Monoclonal Antibody Neurodegenerative Disease Neurology Oncology Orphan Drug Phase 1 trial Phase 2 Trial Phase 3 trial Precision Medicine Precision Oncology rare disease rare diseases Regenerative Medicine targeted therapy
SHELTON, Conn., July 15, 2026 Intensity Therapeutics, Inc. has restarted patient treatment in its Phase 2 INVINCIBLE-4 clinical trial...
FOSTER CITY, Calif., June 24, 2026 Gilead Sciences, Inc. announced that the U.S. Food and Drug Administration (FDA) has...
SANTA CLARA, Calif., June 2, 2026 Agilent Technologies announced that the U.S. Food and Drug Administration (FDA) has approved...
FOSTER CITY, Calif., May 25, 2026 Gilead Sciences announced that the European Medicines Agency’s Committee for Medicinal Products for...
Redmond, Washington, USA – May 21, 2026 SystImmune, Inc. announced that multiple clinical and late-stage development data sets from...
FREMONT, California, May 20, 2026 Personalis announced that the Centers for Medicare & Medicaid Services’ Molecular Diagnostic Services Program...
Washington, D.C. – May 15, 2026 Tigerlily Foundation announced a new collaboration with Bristol Myers Squibb focused on improving...
RAHWAY, N.J., May 12, 2026 Merck announced a major expansion of its oncology research portfolio ahead of the 2026...
